Cargando…

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. Here, we show that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Konno, Yoriyuki, Kimura, Izumi, Uriu, Keiya, Fukushi, Masaya, Irie, Takashi, Koyanagi, Yoshio, Sauter, Daniel, Gifford, Robert J., Nakagawa, So, Sato, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473339/
https://www.ncbi.nlm.nih.gov/pubmed/32941788
http://dx.doi.org/10.1016/j.celrep.2020.108185
_version_ 1783579165734207488
author Konno, Yoriyuki
Kimura, Izumi
Uriu, Keiya
Fukushi, Masaya
Irie, Takashi
Koyanagi, Yoshio
Sauter, Daniel
Gifford, Robert J.
Nakagawa, So
Sato, Kei
author_facet Konno, Yoriyuki
Kimura, Izumi
Uriu, Keiya
Fukushi, Masaya
Irie, Takashi
Koyanagi, Yoshio
Sauter, Daniel
Gifford, Robert J.
Nakagawa, So
Sato, Kei
author_sort Konno, Yoriyuki
collection PubMed
description One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. Here, we show that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS-CoV ortholog. Phylogenetic analyses and functional assays reveal that SARS-CoV-2-related viruses from bats and pangolins also encode truncated ORF3b gene products with strong anti-interferon activity. Furthermore, analyses of approximately 17,000 SARS-CoV-2 sequences identify a natural variant in which a longer ORF3b reading frame was reconstituted. This variant was isolated from two patients with severe disease and further increased the ability of ORF3b to suppress interferon induction. Thus, our findings not only help to explain the poor interferon response in COVID-19 patients but also describe the emergence of natural SARS-CoV-2 quasispecies with an extended ORF3b gene that may potentially affect COVID-19 pathogenesis.
format Online
Article
Text
id pubmed-7473339
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Authors.
record_format MEDLINE/PubMed
spelling pubmed-74733392020-09-08 SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant Konno, Yoriyuki Kimura, Izumi Uriu, Keiya Fukushi, Masaya Irie, Takashi Koyanagi, Yoshio Sauter, Daniel Gifford, Robert J. Nakagawa, So Sato, Kei Cell Rep Report One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. Here, we show that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS-CoV ortholog. Phylogenetic analyses and functional assays reveal that SARS-CoV-2-related viruses from bats and pangolins also encode truncated ORF3b gene products with strong anti-interferon activity. Furthermore, analyses of approximately 17,000 SARS-CoV-2 sequences identify a natural variant in which a longer ORF3b reading frame was reconstituted. This variant was isolated from two patients with severe disease and further increased the ability of ORF3b to suppress interferon induction. Thus, our findings not only help to explain the poor interferon response in COVID-19 patients but also describe the emergence of natural SARS-CoV-2 quasispecies with an extended ORF3b gene that may potentially affect COVID-19 pathogenesis. The Authors. 2020-09-22 2020-09-04 /pmc/articles/PMC7473339/ /pubmed/32941788 http://dx.doi.org/10.1016/j.celrep.2020.108185 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Report
Konno, Yoriyuki
Kimura, Izumi
Uriu, Keiya
Fukushi, Masaya
Irie, Takashi
Koyanagi, Yoshio
Sauter, Daniel
Gifford, Robert J.
Nakagawa, So
Sato, Kei
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
title SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
title_full SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
title_fullStr SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
title_full_unstemmed SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
title_short SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
title_sort sars-cov-2 orf3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473339/
https://www.ncbi.nlm.nih.gov/pubmed/32941788
http://dx.doi.org/10.1016/j.celrep.2020.108185
work_keys_str_mv AT konnoyoriyuki sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT kimuraizumi sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT uriukeiya sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT fukushimasaya sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT irietakashi sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT koyanagiyoshio sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT sauterdaniel sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT giffordrobertj sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT nakagawaso sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant
AT satokei sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant